The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.